Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zoetis Inc. (ZTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zoetis, described as the world’s leading animal health company, uses filings such as Form 8-K to report material events related to its operations, financing activities, governance and shareholder returns.
Recent 8-K filings detail several types of information. Zoetis has reported the completion of a private offering of 0.25% Convertible Senior Notes due 2029, including the terms of the notes, their conversion features, optional redemption provisions and related capped call transactions. Other filings describe the issuance of senior notes due 2028 and 2035 under an existing indenture, as well as a revolving credit agreement that provides a senior unsecured revolving credit facility and replaces a prior credit agreement.
Filings also cover corporate actions affecting shareholders, such as declarations of cash dividends on Zoetis common stock and the use of proceeds from financing transactions to repurchase shares under an existing share repurchase program. Additional 8-Ks report quarterly financial results, guidance updates, and investor presentations, including an Innovation Webcast that outlines the company’s pipeline and strategic approach to addressing unmet medical needs in animals.
Through this page, users can review how Zoetis discloses information about its NYSE-listed common stock, debt obligations, credit facilities and board-level decisions. Stock Titan’s platform associates these filings with AI-powered tools that summarize key terms and highlight items such as note covenants, leverage provisions, dividend declarations and event-driven disclosures, helping readers interpret lengthy documents more efficiently.
Zoetis Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on May 20, 2026, covering director elections, executive pay and other key items. Shareholders will elect twelve directors for one-year terms, cast an advisory vote on executive compensation and choose the future frequency of say-on-pay votes.
They will also vote on ratifying KPMG LLP as independent auditor for 2026 and on a shareholder proposal to permit action by written consent, which the Board recommends voting against. The proxy describes Zoetis’ 2025 performance, including 6% organic operational revenue growth and 7% organic operational adjusted net income growth, as well as extensive board independence, skills and sustainability oversight.
Zoetis Inc. Executive Vice President Keith Sarbaugh reported routine equity compensation activity involving restricted stock units. On March 31, 2026, 1,528.0167 restricted stock units vested and were settled into 1,528 shares of Zoetis common stock, reflecting an exercise or conversion of derivative securities.
To cover tax obligations related to this vesting, 524 common shares were withheld at a price of $118.21 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, Sarbaugh directly held 3,346 shares of Zoetis common stock, along with remaining restricted stock units representing 2,674, 773 and 120 underlying common shares that will vest over future anniversaries if service conditions are met.
FULLER JULIE reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Julie Fuller received a grant of 669.3367 Phantom Stock Units tied to Zoetis common stock. These units were awarded at a reference value of $38.2000 per unit under the Zoetis Supplemental Savings Plan and are settled in cash after she leaves the company.
Following this award, Fuller holds a total of 1247.3931 Phantom Stock Units. Each unit represents a fraction of a phantom share of Zoetis common stock plus cash-equivalent investments, which typically account for around 5% of each unit’s value, so the unit value tracks the Zoetis share price and these cash-equivalent holdings.
Joseph Wetteny reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Chief Financial Officer Joseph Wetteny received a grant of 2,114.7557 phantom stock units on Zoetis common stock. The award was made at a reference value of $38.20 per unit under the Zoetis Supplemental Savings Plan.
Following this grant, Wetteny holds a total of 8,918.3552 phantom stock units. Each phantom stock unit tracks the market value of Zoetis common stock plus a small portion of cash-equivalent investments, and is settled in cash after his separation from service. The award currently corresponds to 712.6923 underlying shares of Zoetis common stock.
Zoetis Inc. Chief Executive Officer Kristin C. Peck received a grant of 4,391.2607 Phantom Stock Units at a reference price of $38.20 per unit. Following this award, she holds a total of 62,802.0367 Phantom Stock Units.
Each Phantom Stock Unit represents a fraction of a phantom share of Zoetis common stock plus cash-equivalent investments, which typically account for around 5% of the unit’s total value. These units were acquired under the Zoetis Supplemental Savings Plan and will be settled in cash after her separation from service.
Driscoll Rimma reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Rimma Driscoll received a grant of 641.7440 phantom stock units on Zoetis common stock at a reference value of $38.2000 per unit. Following this award, she holds a total of 6009.5487 phantom stock units.
Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock plus cash-equivalent investments, which typically make up around 5% of the unit’s total value. These units are settled in cash after her separation from service and may be reallocated among plan investment funds subject to Zoetis’ transfer rules.
Esch Kevin reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Kevin Esch received a grant of 219.9529 phantom stock units on Zoetis common stock. The award, valued using a reference price of $38.20 per unit, increased his holdings to 496.9909 phantom stock units, representing an economic interest tied to Zoetis shares.
Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock plus cash-equivalent investments, which typically account for around 5% of the unit’s total value. These units are settled in cash after Esch’s separation from service, with 74.1262 underlying common shares linked to this particular grant.
Zoetis Inc. Executive Vice President Ferran Astorga Jeannette received a grant of 593.1735 Phantom Stock Units on Zoetis common stock, valued at $38.20 per unit. Each unit represents a fraction of a phantom share plus cash-equivalent investments, referencing Zoetis’ market value.
The grant corresponds to 199.9050 underlying shares of common stock, bringing the executive’s total Phantom Stock Units to 2,245.8327. These units, acquired under the Zoetis Supplemental Savings Plan, are cash-settled after separation from service and may be reallocated among investment funds subject to Zoetis’ transfer limits.
Zoetis Inc. Executive Vice President Keith Sarbaugh received a grant of 626.6723 phantom stock units on Zoetis common stock. Each phantom stock unit was valued at $38.20 and corresponds to 211.1944 underlying shares of common stock. Following this grant, his phantom stock unit balance is 1,874.4329 units. These units were acquired under the Zoetis Supplemental Savings Plan and are settled in cash after his separation from service, with value tied to Zoetis’ share price and a small portion in cash-equivalent investments.